Oxford Nanopore welcomes Dr Guy Harmelin as a non-executive Director
Guy has extensive experience in healthcare and technology investment and entrepreneurship. He was previously on the leadership team at Harel Insurance Investments and Financial Services, the largest insurance group in Israel with over $71 billion in assets under management. Guy has invested and worked with multiple successful companies including Lemonade, Innoviz, American Well, Ecoppia, Ayala Pharma, Biond Biologics, Tabit, Assured Allies, Quantum Machines, Rafael and Ein-Tal Hospitals.
Prior to joining Harel, Guy was the Co-Founder and CEO of RondinX, a computational drug target discovery Company which merged with BiomX and went public on NYSE in November 2019, PHGE.
Guy has an MD Summa Cum Laude from the University of Florence and served as a Resident Physician at the Tel Aviv Medical Center.
“We are delighted to welcome Dr Guy Harmelin to our board,” said Dr Gordon Sanghera, CEO. “With extensive experience across multiple healthcare and tech businesses, and professional medical qualifications and experience, Guy joins at a time when nanopore sequencing products are closer than ever to providing beneficial insights to patients.”
